Atea Pharmaceuticals Inc (AVIR) rating upgrades by Morgan Stanley

Atea Pharmaceuticals Inc’s filing revealed that its Director BERGER FRANKLIN M unloaded Company’s shares for reported $1.02 million on Dec 10 ’24. In the deal valued at $2.85 per share,359,606 shares were sold. As a result of this transaction, BERGER FRANKLIN M now holds 451,897 shares worth roughly $1.33 million.

Then, Franklin Berger bought 359,606 shares, generating $1,023,475 in total proceeds.

Before that, Sommadossi Jean-Pierre sold 33,941 shares. Atea Pharmaceuticals Inc shares valued at $137,318 were divested by the President, CEO, and Chairman at a price of $4.05 per share. As a result of the transaction, Sommadossi Jean-Pierre now holds 5,890,053 shares, worth roughly $17.38 million.

Morgan Stanley upgraded its Atea Pharmaceuticals Inc [AVIR] rating to an Equal-weight from a an Underweight in a research note published on August 13, 2024; the price target was increased to $6.88 from $2. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in early August from “a Neutral” to “an Underweight”. Morgan Stanley also remained covering AVIR and has decreased its forecast on January 06, 2022 with a “an Underweight” recommendation from previously “an Equal-weight” rating. SVB Leerink revised its rating on November 18, 2021. It rated AVIR as “a Mkt perform” which previously was an “an Outperform”.

Price Performance Review of AVIR

On Tuesday, Atea Pharmaceuticals Inc [NASDAQ:AVIR] saw its stock jump 1.72% to $2.95. Over the last five days, the stock has gained 4.98%. Atea Pharmaceuticals Inc shares have fallen nearly -11.94% since the year began. Nevertheless, the stocks have fallen -22.77% over the past one year. While a 52-week high of $4.14 was reached on 01/03/25, a 52-week low of $2.45 was recorded on 05/15/25. SMA at 50 days reached $2.90, while 200 days put it at $3.23.

Levels Of Support And Resistance For AVIR Stock

The 24-hour chart illustrates a support level at 2.87, which if violated will result in even more drops to 2.79. On the upside, there is a resistance level at 3.03. A further resistance level may holdings at 3.10. The Relative Strength Index (RSI) on the 14-day chart is 55.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 13.16%. Stochastics %K at 82.89% indicates the stock is a selling.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.